Since acquiring the Sainte-Foy, Quebec facility in 2005, GSK has invested $200 million in that facility, a timely investment that enabled GSK to provide the entire supply required for Canada to address the H1N1 threat and handle over 50 million eggs in the production of the H1N1 vaccine.
Depuis l'acquisition de son centre de production de vaccins à Ste-Foy, au Québec, en 2005, GSK y a investi 200 millions de dollars.